Susquehanna maintains a 'Positive' rating on Mindray Medical (NYSE: MR), raises price target from $37 to $44.

Susquehanna analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE